Open Journal Systems

Research Progress in Bladder Cancer Diagnosis and Therapy

VIEWS - 111 (Abstract) 33 (PDF)
Xuanhe Chen, Xue Tan, Fangjing Fan, Chong Li


Bladder cancer is one of the most frequent malignancies associated with high morbidity, high mortality, as well as inconvenient post-operative recurrence. Typical symptoms of bladder cancer include hematuria, frequent urination, nocturia, and dysuria. Most of the primary bladder tumors are non-muscle invasive, which do not grow in muscularis propria, and are often treated with surgery. Muscle-invasive tumors are more common in recurrent diseases, which have higher risk of metastasis. In addition, the treatments of these tumors have more serious side effects such as radical cystectomy with neoadjuvant chemotherapy. The mechanisms of pathogenesis and metabolisms of bladder cancer are yet unclear. However, several genetic mutations and influences from external environment have been proven to be the risk factors for bladder cancer. Along with the developments in researches, the understanding about bladder cancer formation and treatment has been improved over the years. Further studies on medical detection through new technologies are beneficial to the diagnosis and treatment of bladder cancer. This review aimed to provide a general view of some recent progresses of bladder cancer’s pathogenesis, diagnosis, treatment, and developments on research methods.


Bladder cancer, Pathogenesis, Diagnosis, Treatment, Translational medicine, Precision medicine

Full Text:



Bladder Cancer Symptoms, Tests, Prognosis, and Stages; 2019. Available from: bladder/patient/about-bladder-cancer-pdq. [Last accessed on 2019 May 18].

Han S, Zhang S, Chen W, et al., 2013, Analysis of the Status and Trends of Bladder Cancer Incidence in China. Oncol Prog, 6:89-95.

Han S, Zhang S, Chen W, et al., 2013, Analysis of the Status Quo and Trends: Mortality in Patients with Bladder Cancer in China. J Mod Urol, 18:228-32.

Kamat AM, Hahn NM, Efstathiou JA, et al., 2016, Bladder Cancer. Lancet, 388:2796-810.

Turo R, Cross W, Whelan P, 2011, Bladder Cancer. Common Cancers, 40:14-9.

Zhang R, Zhang J, He Z, et al., 2003, Research Advances on Bladder Cancer Associated Genes. Chin J Cancer, 24:104-7.

Yang Z, Li C, Fan Z, et al., 2017, Single-cell Sequencing Reveals Variants in ARID1A, GPRC5A and MLL2 Driving Self-renewal of Human Bladder Cancer Stem Cells. Eur Urol, 71:8-12. DOI 10.1016/j.eururo.2016.06.025.

Wu S, Huang P, Li C, et al., 2014, Telomerase Reverse Transcriptase Gene Promoter Mutations Help Discern the Origin of Urogenital Tumors: A Genomic and Molecular Study. Eur Urol, 65:274-7. DOI 10.1016/j. eururo.2013.10.038.

Li C, Wu S, Wang H, et al., 2015, The C228T Mutation of TERT Promoter Frequently Occurs in Bladder Cancer Stem Cells and Contributes to Tumorigenesis of Bladder Cancer. Oncotarget, 23:19542-51. DOI 10.18632/oncotarget.4295.

Li C, Du Y, Yang Z, et al., 2016, GALNT1-mediated Glycosylation and Activation of Sonic Hedgehog Signaling Maintains the Self-renewal and Tumor-initiating Capacity of Bladder Cancer Stem Cells. Cancer Res, 76:1273-83. DOI 10.1158/0008-5472.can-15-2309.

Brennan P, Bogillot O, Cordier S, et al., 2000, Cigarette Smoking and Bladder Cancer in Men: A Pooled Analysis of 11 Case-control Studies. Int J Cancer, 86:289-94. DOI 10.1002/(sici)1097-0215(20000415)86:2<289:aid-ijc21>;2-m.

Joshi M, Millis SZ, Arguello D, et al., 2018, Molecular Characterization of Bladder Cancer in Smokers Versus Nonsmokers. Eur Urol, 4:94-7.

Li K, Lin T, Chinese Bladder Cancer Consortium, et al., 2015, Current Status of Diagnosis and Treatment of Bladder Cancer in China Analyses of Chinese Bladder Cancer Consortium Database. Asian J Urol, 2:63-9.

Xin Z, Zhao Y, Xu J, et al., 2017, Gene Expression Profiling and Construction of a Putative Gene Regulatory Network of Bladder Cancer Tumor-initiating Cells. Oncotarget, 8:111271-80. DOI 10.18632/oncotarget.22771.

Ding M, Li Y, Lv Y, et al., 2015, Diagnostic Value of Urinary MicroRNAs as Non-invasive Biomarkers for Bladder Cancer: A meta-analysis. Int J Clin Exp Med, 8:15432-40.

Song W, Zhao Y, Rui Y, et al., 2015, Novel Variants in MLL Confer to Bladder Cancer Recurrence Identified by Whole-exome Sequencing. Oncotarget, 7:2629-45.

Zhao Y, Zhang R, Ge Y, et al., 2018, Somatic FGFR3 Mutations Distinguish a Subgroup of Muscle-invasive Bladder Cancers with Response to Neoadjuvant Chemotherapy. EBioMedicine, 35:198-203. DOI 10.1016/j. ebiom.2018.06.011.

Chen Y, Wang H, Zuo Y, et al., 2018, A Novel Monoclonal Antibody KMP1 has Potential Antitumor Activity of Bladder Cancer by Blocking CD44 in vivo and in vitro. Cancer Med, 7:1-14. DOI 10.1002/cam4.1446.

Zhu L, Chen N, Dong B, et al., 2016, A Novel Hedgehog Inhibitor iG2 Suppresses Tumorigenesis by Impairing Self-renewal in Human Bladder Cancer. Cancer Med, 5:2579-86. DOI 10.1002/cam4.802.

Zhao Y, He L, Lin K, et al., 2017, The KMT1A-GATA3- STAT3 Circuit is a Novel Self-renewal Signaling of Human Bladder Cancer Stem Cells. Clin Cancer Res, 23:1-13. DOI 10.1158/1078-0432.ccr-17-0882.

Li C, Zhao Y, Ying D, et al., 2014, BCMab1, a Monoclonal Antibody Against Aberrantly Glycosylated Integrin a3b1, has Potent Antitumor Activity of Bladder Cancer in vivo. Clin Cancer Res, 20:4001-13. DOI 10.1158/1078-0432.ccr- 13-3397.

Li C, Yan R, Zhao Y, et al., 2016, BCMab1-Ra, a Novel Immunotoxin that BCMab1 Antibody Coupled to Ricin a Chain, Can Eliminate Bladder Tumor. Oncotarget, 8:46704-5. DOI 10.18632/oncotarget.13504.

Bilsen MP, Meijgaarden KE, Jong HK, et al., 2018, A Novel View on the Pathogenesis of Complications after Intravesical BCG for Bladder Cancer. Int J Infect Dis, 72:63-8. DOI 10.1016/j.ijid.2018.05.006.

Hsueh TY, Chiu AW, 2016, Narrow Band Imaging for Bladder Cancer. Asian J Urol, 3:126-9.

Brieu N, Gavriel CG, Nearchou IP, et al., 2019, Automated Tumour Budding Quantifcation by Machine Learning Augments TNM Staging in Muscle Invasive Bladder Cancer Prognosis. Sci Rep, 9:5174. DOI 10.1038/s41598- 019-41595-2.

Li C, Yan R, Bao J, et al., 2006, Characterization of a Novel Transplantable Orthotopic Murine Xenograft Model of a Human Bladder Transitional Cell Tumor (biu-87). Cancer Biol Ther, 5:394-8. DOI 10.4161/cbt.5.4.2509.



  • There are currently no refbacks.

Copyright (c) 2019 Li, et al.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Recent Articles | About Journal | For Author | Fees | About Whioce

Copyright © Whioce Publishing Pte Ltd. All Rights Reserved.